Program
DNV001
A development code. Also written as “DNV001 Injection”.
Its studies are mostly in Hypercholesterolemia, led by Hangzhou Dinovate Biotech.
Furthest: phase 2, since Dec 14, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Dinovate Biotech | 11 open or running | phase 2since Dec 14, 2025 | Dec 14, 2025 | Jun 30, 2027phase 2 · NCT07391722 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 14, 2025First study: phase 2 study in HypercholesterolemiaFirst studyNCT07391722 · 120 planned
Ahead
- Jun 30, 2027Primary completion: phase 2 study in HypercholesterolemiaNCT07391722
TargetBeta
PCSK9 →read by rule
“DNV001 is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), administered as a sterile solution for subcutaneous injection.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07391722Hypercholesterolemia | 2 | Not yet recruiting | Jun 30, 2027 | 120 |
How it is read
Names in the registry
- “DNV001 Injection”, 1 entry
Codes read as this program: DNV001.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.